124 related articles for article (PubMed ID: 33207248)
1. Famciclovir leads to failure of hematopoiesis, but may have the benefit of relieving myeloid expansion in MDS-like zebrafish.
Li J; Meng P; Zhou R; Zhang Y; Lin Q
Toxicol Appl Pharmacol; 2021 Jan; 410():115334. PubMed ID: 33207248
[TBL] [Abstract][Full Text] [Related]
2. Quercetin induces autophagy in myelodysplastic bone marrow including hematopoietic stem/progenitor compartment.
Daw S; Law S
Environ Toxicol; 2021 Feb; 36(2):149-167. PubMed ID: 32902906
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory signaling regulates hematopoietic stem and progenitor cell emergence in vertebrates.
He Q; Zhang C; Wang L; Zhang P; Ma D; Lv J; Liu F
Blood; 2015 Feb; 125(7):1098-106. PubMed ID: 25540193
[TBL] [Abstract][Full Text] [Related]
4. c-myb hyperactivity leads to myeloid and lymphoid malignancies in zebrafish.
Liu W; Wu M; Huang Z; Lian J; Chen J; Wang T; Leung AY; Liao Y; Zhang Z; Liu Q; Yen K; Lin S; Zon LI; Wen Z; Zhang Y; Zhang W
Leukemia; 2017 Jan; 31(1):222-233. PubMed ID: 27457538
[TBL] [Abstract][Full Text] [Related]
5. Establishment of a zebrafish hematological disease model induced by 1,4-benzoquinone.
Zhang A; Wu M; Tan J; Yu N; Xu M; Yu X; Liu W; Zhang Y
Dis Model Mech; 2019 Mar; 12(3):. PubMed ID: 30898970
[TBL] [Abstract][Full Text] [Related]
6. Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells.
Wobus M; Mies A; Asokan N; Oelschlägel U; Möbus K; Winter S; Cross M; Weidner H; Rauner M; Hofbauer LC; Bornhäuser M; Platzbecker U
Leukemia; 2021 Oct; 35(10):2936-2947. PubMed ID: 34002031
[TBL] [Abstract][Full Text] [Related]
7. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.
Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F
Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566
[TBL] [Abstract][Full Text] [Related]
8. Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS.
Follo MY; Marmiroli S; Faenza I; Fiume R; Ramazzotti G; Martelli AM; Gobbi P; McCubrey JA; Finelli C; Manzoli FA; Cocco L
Adv Biol Regul; 2013 Jan; 53(1):2-7. PubMed ID: 23058275
[TBL] [Abstract][Full Text] [Related]
9. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors.
Plasilova M; Zivny J; Jelinek J; Neuwirtova R; Cermak J; Necas E; Andera L; Stopka T
Leukemia; 2002 Jan; 16(1):67-73. PubMed ID: 11840265
[TBL] [Abstract][Full Text] [Related]
10. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
[TBL] [Abstract][Full Text] [Related]
11. Control of hematopoiesis and apoptosis in MDS: more than FLIPing the coin.
Mhyre AJ; Deeg HJ
Leuk Res; 2007 Jun; 31(6):747-9. PubMed ID: 17320170
[No Abstract] [Full Text] [Related]
12. Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes.
Balaian E; Weidner H; Wobus M; Baschant U; Jacobi A; Mies A; Bornhäuser M; Guck J; Hofbauer LC; Rauner M; Platzbecker U
Ann Hematol; 2019 Sep; 98(9):2063-2072. PubMed ID: 31312928
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow niche in the myelodysplastic syndromes.
Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
[TBL] [Abstract][Full Text] [Related]
14. What is the role of the microenvironment in MDS?
Calvi LM; Li AJ; Becker MW
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101113. PubMed ID: 31779976
[TBL] [Abstract][Full Text] [Related]
15. Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes.
Maratheftis CI; Andreakos E; Moutsopoulos HM; Voulgarelis M
Clin Cancer Res; 2007 Feb; 13(4):1154-60. PubMed ID: 17317824
[TBL] [Abstract][Full Text] [Related]
16. S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes.
Cheng P; Eksioglu EA; Chen X; Kandell W; Le Trinh T; Cen L; Qi J; Sallman DA; Zhang Y; Tu N; Adams WA; Zhang C; Liu J; Cleveland JL; List AF; Wei S
Leukemia; 2019 Aug; 33(8):2034-2046. PubMed ID: 30737486
[TBL] [Abstract][Full Text] [Related]
17. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes.
Tauro S; Hepburn MD; Bowen DT; Pippard MJ
Haematologica; 2001 Oct; 86(10):1038-45. PubMed ID: 11602409
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo.
Knorr KL; Finn LE; Smith BD; Hess AD; Foran JM; Karp JE; Kaufmann SH
Stem Cells Transl Med; 2017 Mar; 6(3):840-850. PubMed ID: 28297583
[TBL] [Abstract][Full Text] [Related]
19. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
Pellagatti A; Boultwood J
Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
[TBL] [Abstract][Full Text] [Related]
20. MDS-like experimental myelodysplasia: multilineage abnormal hematopoiesis in transgenic mice harboring the SV40 large T antigen under an immunoglobulin enhancer.
Furuta Y; Aizawa S; Suda Y; Ikawa Y; Nishikawa S; Hayashi S; Hirabayashi Y; Inoue T
Exp Hematol; 1993 Jun; 21(6):806-15. PubMed ID: 8500578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
